ResMed Inc. (RMD)
| Market Cap | 28.66B -22.2% |
| Revenue (ttm) | 5.54B +10.3% |
| Net Income | 1.52B +15.7% |
| EPS | 10.37 +16.4% |
| Shares Out | 144.42M |
| PE Ratio | 19.31 |
| Forward PE | 16.50 |
| Dividend | $2.40 (1.21%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | 1,396,024 |
| Open | 201.00 |
| Previous Close | 200.29 |
| Day's Range | 197.65 - 202.08 |
| 52-Week Range | 180.27 - 293.81 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 260.60 (+31.33%) |
| Earnings Date | Jul 30, 2026 |
About RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring... [Read more]
Financial Performance
In fiscal year 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for RMD stock is "Buy." The 12-month stock price target is $260.6, which is an increase of 31.33% from the latest price.
News
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
Angelini Ventures marks its first portfolio exit as ResMed acquires Noctrix Health, validating its strategy of backing breakthrough healthcare innovation.
ResMed Transcript: 46th Annual William Blair Growth Stock Conference
Operating in a vast, under-penetrated market, the company leverages innovation, strategic acquisitions, and digital health partnerships to drive growth and patient engagement. Strong financial performance supports increased R&D, share buybacks, and expansion into new therapy areas like Restless Legs Syndrome.
ResMed Slides: 46th Annual William Blair Growth Stock Conference
ResMed has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). Acquisition a...
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the...
Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world...
ResMed beats quarterly profit estimates, names new CFO
Medical device maker ResMed beat third‑quarter profit estimates on Thursday, driven by strong demand for its medical devices, while appointing Aaron Bloomer as its new chief financial officer.
ResMed Earnings Call Transcript: Q3 2026
Q3 FY26 saw 11% revenue growth, 21% non-GAAP EPS growth, and strong margin expansion. Announced Noctrix Health acquisition and CFO transition, with robust cash flow and continued investment in innovation and shareholder returns.
ResMed Earnings release: Q3 2026
ResMed released its Q3 2026 earnings on April 30, 2026, summarizing the period's financial results.
ResMed Slides: Q3 2026
ResMed has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on April 30, 2026.
ResMed Quarterly report: Q3 2026
ResMed has published its Q3 2026 quarterly earnings report on April 30, 2026.
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett...
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% GAAP income from operations increased 17%...
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, ...
Resmed's Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains 53% of people surveyed rank sleep as the most important behavior for a long, h...
ResMed At $250: Missed Opportunity Or A Trap In The Making?
ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, maint...
Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distributi...
Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge
Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1 bo...
ResMed beats quarterly profit estimates on strong demand for its sleep devices
Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep apnea.
ResMed Earnings Call Transcript: Q2 2026
Q2 FY2026 saw 11% revenue growth and 16% EPS growth, with strong performance in devices and masks, margin expansion, and robust cash flow. Continued investments in R&D, SG&A, and capital returns underpin confidence in sustained growth.
ResMed Quarterly report: Q2 2026
ResMed has published its Q2 2026 quarterly earnings report on January 29, 2026.
ResMed Earnings release: Q2 2026
ResMed released its Q2 2026 earnings on January 29, 2026, summarizing the period's financial results.
ResMed Slides: Q2 2026
ResMed has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on January 29, 2026.
Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong revenue growth, margin expansion, and global reach are supported by innovation in AI-enabled devices, digital health, and strategic acquisitions. Big Tech and GLP-1 trends are driving patient flow, while U.S. manufacturing expansion and regulatory wins strengthen market position.